Overview

• Pfizer agreed to align prices for newly launched medicines with other developed markets and to take steps so U.S. patients pay comparable prices for existing drugs.
• The company will sell directly to Americans through TrumpRx.gov, offering significant discounts reported as up to 85% with an average near 50% on many primary care and select specialty brands.
• Under the agreement, Pfizer is exempt from the 100% tariff on pharmaceutical imports that took effect on October 1.
• Shares climbed 6.83% to $25.48 in the latest session after investors reacted to the pricing deal and tariff relief.
• Cantor Fitzgerald’s Carter Gould reiterated a Hold rating with a $24 price target as Pfizer pursues growth via major deals, including the Seagen acquisition and a planned $4.9 billion purchase of Metsera.